Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. | Read by QxMD (original) (raw)

Eiji Kikuchi, Vitaly Margulis, Pierre I Karakiewicz, Marco Roscigno, Shuji Mikami, Yair Lotan, Mesut Remzi, Christian Bolenz, Cord Langner, Alon Weizer, Francesco Montorsi, Karim Bensalah, Theresa M Koppie, Mario I Fernández, Jay D Raman, Wassim Kassouf, Christopher G Wood, Nazareno Suardi, Mototsugu Oya, Shahrokh F Shariat

PURPOSE: To assess the association of lymphovascular invasion (LVI) with cancer recurrence and survival in a large international series of patients treated with radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC).

PATIENTS AND METHODS: Data were collected on 1,453 patients treated with RNU at 13 academic centers and combined into a relational database. Pathologic slides were rereviewed by genitourinary pathologists according to strict criteria. LVI was defined as presence of tumor cells within an endothelium-lined space.

RESULTS: LVI was observed in 349 patients (24%). Proportion of LVI increased with advancing tumor stage, high tumor grade, presence of tumor necrosis, sessile tumor architecture, and presence of lymph node metastasis (all P < .001). LVI was an independent predictor of disease recurrence and survival (P < .001 for both). Addition of LVI to the base model (comprising pathologic stage, grade, and lymph node status) marginally improved its predictive accuracy for both disease recurrence and survival (1.1%, P = .03; and 1.7%, P < .001, respectively). In patients with negative lymph nodes and those in whom a lymphadenectomy was not performed (n = 1,313), addition of LVI to the base model improved the predictive accuracy of the base model for both disease recurrence and survival by 3% (P < .001 for both). In contrast, LVI was not associated with disease recurrence or survival in node-positive patients (n = 140).

CONCLUSION: LVI was an independent predictor of clinical outcomes in nonmetastatic patients who underwent RNU for UTUC. Assessment of LVI may help identify patients who could benefit from multimodal therapy after RNU. After confirmation, LVI should be included in staging of UTUC.